The invention relates to thienopyridazinones of formula (I): wherein: R
1
is C
1-6
alkyl, C
2-6
alkenyl or C
3-6
cycloalkyl which is optionally substituted by C
1-6
alkyl, each of the above being optionally substituted by one or more halogen atoms; R
2
is C
1-6
alkyl; R
3
is a group CO-G or SO
2
-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C
1-4
alkyl; Q is CR
5
R
6
where R
5
and R
6
are as defined in the specification; and R
4
is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.
THIENOPYRIDAZINONE DERIVATIVE AS MODULATORS OF AUTOIMMUNE DISEASES
申请人:AstraZeneca AB
公开号:EP1587809B1
公开(公告)日:2007-10-10
US7064126B2
申请人:——
公开号:US7064126B2
公开(公告)日:2006-06-20
Development of novel pyridazinone-based adenosine receptor ligands
作者:Daniela Catarzi、Flavia Varano、Matteo Falsini、Katia Varani、Fabrizio Vincenzi、Silvia Pasquini、Diego Dal Ben、Vittoria Colotta
DOI:10.1016/j.bmcl.2018.03.086
日期:2018.5
With the aim of finding new adenosine receptor (AR) ligands, a preliminary investigation focusing on the thieno[2,3-d]pyridazin-5(4H)-one scaffold was undertaken. The synthesized compounds 1–11 were evaluated for their binding at hA1, hA2A and hA3 ARs and efficacy at hA2B subtype in order to determine the affinity at the human adenosine receptor subtypes. Small structural changes on this scaffold highly